TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Thursday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Down 0.5 %

Shares of TXMD opened at $1.86 on Thursday. TherapeuticsMD has a 52-week low of $1.86 and a 52-week high of $4.73. The stock has a fifty day simple moving average of $2.22 and a two-hundred day simple moving average of $2.30.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC bought a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned about 2.57% of TherapeuticsMD at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.